NVPCA MAT Clinical Modules
On Demand
Team-Based Care
A team-based approach to caring for patients with OUD in a primary care or office-based setting can reduce barriers to MAT and improve health outcomes. In this presentation, Ms. Amanda Brooks discusses key components of office-based models for MAT and example workflows. Participants will learn to (1) understand the types of opioid use disorder (OUD) treatment models in primary care and (2) recognize the roles that various staff members can play in delivery of OUD treatment.
After completing the video, please fill out the evaluation for this module
*The survey link is also included on the Vimeo video page
Toxicology
Understanding and interpreting urine toxicology results for patients with OUD can be challenging. Results may vary depending on the patient’s treatment process and individual progress. In this presentation, Dr. Elizabeth Salisbury Afshar discusses how to use and interpret urine drug screens when caring for patients with OUD. Using a case scenario, Dr. Salisbury-Afshar demonstrates practical concerns and key decision points to help participants apply urine drug testing (UDT) results effectively in their care of patients with OUD. Clinical providers and MAT team members will learn to (1) describe how UDT can be used for monitoring treatment adherence, ongoing opioid use, and polysubstance use; (2) interpret toxicology results; (3) understand diversion prevention; and (4) address polysubstance use.
After completing the video, please fill out the evaluation for this module
*The survey link is also included on the Vimeo video page
OUD and HIV/HCV
A significant number of people with Opioid Use Disorder (OUD) also experience co-occurring illnesses such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV), making their care more complex. In this presentation, Dr. Megan Buresh discusses treatment of opioid use disorder (OUD) in patients with HIV or HCV. Clinical providers and other MAT team members will learn how to screen patients for OUD when they present with an infectious disease, co-administer and manage OUD medications and antiretroviral therapy (ART), and encourage harm reduction practices among patients
After completing the video, please fill out the evaluation for this module
*The survey link is also included on the Vimeo video page
Intake Assessment
A significant When caring for patients with OUD, initial intake assessment sets the tone for a patient’s treatment plan and initiation of Medications for Addiction Treatment (MAT). Intake incorporates medical, psychiatric, and substance use history, screening for mental illness, evaluation of family and psychosocial supports, physical examination, prescription monitoring, and urine toxicology. In this presentation, Dr. Nicky Gastala discusses screening tools, DSM-5 diagnostic criteria for OUD, and approaches to medication initiation, including when to consider initiation of buprenorphine in the home or office setting. Clinical providers and other MAT team members will learn to (1) perform an assessment for MAT; (2) conduct a withdrawal assessment; (3) manage precipitated withdrawal; and (4) electronically prescribe MAT.
After completing the video, please fill out the evaluation for this module
*The survey link is also included on the Vimeo video page